conclusion:
In conclusion, our case shows that a single occurrence of infusion-related reactions with crizanlizumab does not necessarily equate to recurrence. Therefore, the long-term overall efficacy of the drug must be considered before a decision is made to discontinue it prematurely. In the specific case of our SCD patient, treatment with crizanlizumab showed hopeful results in stuttering priapism, an observation that needs to be confirmed by other similar cases and real-world evidence.